Trademark Overview
On Monday, May 19, 2025, a trademark application was filed for CORTEXA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the CORTEXA THERAPEUTICS trademark a serial number of 99192698. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, May 19, 2025. This trademark is owned by Cortexa Therapeutics, Inc.. The CORTEXA THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:
Providing medical information in the field of Amyotrophic Lateral Sclerosis (ALS); Pharmaceutical advice; Providing health information in the field of Central Nervous System (CNS) disorders; Medical analysis services relating to the treatment of persons; Providing information in the field of the diagnosis and treatment of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), Huntington’s Disease, and vascular dementia via a website; Consulting services in the field of the diagnosis and treatment of Amyotrophic Lateral Sclerosis (ALS); Consulting services to health care providers in the field of treating life-changing or life-threatening diseases; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of Central Nervous System (CNS) disorders; Medical screening services in the field of Central Nervous System (CNS) disorders
Biotechnology research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the field of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), Huntington’s Disease, and vascular dementia; Scientific research for medical purposes in the field of Central Nervous System (CNS) disorders; Scientific study and research in the field(s) of treatment and management of CNS disorders; Laboratory research services relating to pharmaceuticals; Clinical research in the field of Central Nervous System (CNS) disorders medical treatment; Testing of pharmaceuticals; Scientific research in the nature of conducting clinical trials for others in the field of Central Nervous System (CNS) disorders treatments; Research and development services in the field of pharmaceutical preparations; Laboratory services for biomanufacturing CRO-contracted compounds; Laboratory research in the fie...
